B
Boston Pharmaceuticals
Acquiring and transforming innovative molecules into differentiated medicines that improve patients’ lives
About Boston Pharmaceuticals
Boston Pharmaceuticals operates as a clinical-stage biopharmaceutical company with a distinct business model focused on acquiring and developing promising drug candidates. Founded in 2015 by Chris Viehbacher and Robert Armstrong, the company identifies and in-licenses molecules from other biotechnology and pharmaceutical firms that have shown early potential. This strategy allows Boston Pharmaceuticals to bypass the initial, often high-risk, stages of drug discovery and apply its team's expertise to advance these assets through clinical development. The company's revenue model is centered on creating value by achieving clinical proof-of-concept and then partnering with larger pharmaceutical companies for late-stage development, registration, and commercialization, or in some cases, advancing programs on its own.
Read full description
The company was established with significant initial capital, reportedly $600 million from Gurnet Point Capital, to build a diverse portfolio of early-stage drug candidates. This financial backing enables the company to pursue multiple programs simultaneously across various therapeutic areas. Co-founder Chris Viehbacher brought extensive experience from his time as CEO of Sanofi and a 20-year career at GlaxoSmithKline (GSK), providing a deep understanding of pharmaceutical R&D and a vast industry network. This background is integral to the company's strategy of identifying high-potential assets and forging partnerships, such as a multi-program agreement with GSK announced in 2018.
Currently, Boston Pharmaceuticals is primarily focused on developing therapies for serious liver diseases. Its lead program was efimosfermin alfa (BOS-580), a long-acting FGF21 analogue for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. After showing statistically significant improvements in liver fibrosis and MASH resolution in a Phase 2 study, the asset was acquired by GSK. The company's pipeline has also included candidates for autoimmune diseases, cancer, irritable bowel syndrome, and acne. By employing a data-driven approach and leveraging a network of development partners, Boston Pharmaceuticals aims to de-risk and accelerate the journey of new medicines to patients.
At a glance
- Status
- Acquired
- Founded
- 2016
- Headquarters
- Cambridge, United States
- Employees
- 70
- Open positions
- None listed
- Dealroom signal
- 30.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Oct 2025 | $1.2B | $1.2B | GSK | ↗ |
| GROWTH EQUITY VCOther financing | Sep 2017 | $600M | — | Gurnet Point Capital | ↗ |
Growth signals
Latest recorded traffic for Boston Pharmaceuticals is 690 monthly website visits, down 37.3% over the last three months. Boston Pharmaceuticals's team declined 16.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Gurnet Point Capital
Other known investors1 additional known investor
GSK
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Boston Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Boston Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.